An official website of the United States government
Here’s how you know
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Joseph W. Robertson, Madhav Ghimire, Joseph Reiner
Protein nanopores have emerged as an important class of sensor, for the understanding of biophysical processes, such as molecular transport across membranes, and detection and characterization of biopolymers. We trace the development of these sensors from
Concepcion Remoroza, Meghan Burke Harris, Yi Liu, Yuri Mirokhin, Dmitrii V. Tchekhovskoi, Xiaoyu (Sara) Yang, Stephen E. Stein
A method for representing and comparing distributions of N-linked glycans located at specific sites in proteins is presented. The representation takes the form of a simple mass spectrum for a given peptide sequence, with each peak corresponding to a
Eric Deutsch, Yasset Perez-Riverol, Jeremy Carver, Shin Kawano, Luis Mendoza, Tim Van Den Bossche, Ralf Gabriels, Pierre-Alain Binz, Benjamin Pullman, Zhi Sun, Jim Shofstahl, Wout Bittremeieux, Tytus Mak, Joshua Klein, Yunping Zhu, Henry Lam, Juan Antonio Vizcaino, Nuno Bandeira
Mass spectra provide the ultimate evidence to support the findings of mass spectrometry proteomics studies in publications, and it is therefore crucial to be able to trace the conclusions back to the spectra. The Universal Spectrum Identifier (USI)
Kyle Anderson, Kerry Scott, Ioannis Karageorgos, Elyssia Gallagher, Venkata Tayi, Michael Butler, Jeffrey W. Hudgens
This database gives hydrogen-deuterium exchange mass spectrometry (HDX-MS) data from measurements of three purified IgG1 glycoform samples, predominantly G0F, G2F, and SAF, in isolation and in complexation with the high-affinity receptor, FcγR1a (CD64)
Ben Neely, Michael G. Janech, Alison Bland, Brock Fenton, Nancy B. Simmons, Daniel J. Becker
Bats (Order: Chiroptera) are increasingly studied as model systems for longevity and for their ability to seemingly tolerate typically virulent viruses without showing clinical disease. Yet our ability to characterize immune mechanisms of viral tolerance
Santica Marcovina, Noemie Clouet-Foraison, Marlys Koschinsky, Mark Lowenthal, Michael Boffa, Andrew Hoofnagle, Tomas Vaisar
Background: Use of Lipoprotein(a) levels for identification of individuals at high risk for cardiovascular disease is hampered by the high size polymorphism of apolipoprotein(a) which strongly impacts immunochemical methods resulting in discordant values
Cloud hosted environments offer known benefits when computational needs outstrip affordable local workstations, enabling high-performance compute without a physical cluster. What has been less apparent, especially to novice users, is the transformative
Sean Lehman, Ioannis Karageorgos, Wyatt N. Vreeland, Jeremy Filteau
Protein aggregation can affect the quality of protein-based therapeutics and is an important aspect of disease progression in multiple illnesses. Attempting to unravel the mechanisms and factors influencing protein aggregation involves systematic studies
Next-generation approaches for protein sequencing are now emerging that could have the potential to revolutionize the field in proteomics. One such sequencing method involves fluorescence-based imaging of immobilized peptides in which the N-terminal amino
For the last century we have relied on model organisms to help understand fundamental biological processes. Now, with advancements in genome sequencing, assembly and annotation, non-model organisms may be studied with the same advanced bioanalytical
Christina Bergonzo, Jennifer A. Tullman, Kunal Dharmadhikari, Emily Samuels, Makenzie Christensen
ClpS is a small protein currently under development as a probe for detecting specific N-terminal amino acids of peptides. In order for ClpS to be used in this manner, it is important to understand the structural reasons for how and why ClpS recognizes
Adoptive cell therapy is an emerging anti-cancer modality, whereby the patients own immune cells are engineered to express T-cell receptor (TCR) or chimeric antigen receptor (CAR). CAR-T cell therapies have advanced the furthest, with recent approvals of